Rhumbline Advisers Has $3.91 Million Position in Xencor, Inc. (NASDAQ:XNCR)

Rhumbline Advisers lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 11.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 170,000 shares of the biopharmaceutical company’s stock after acquiring an additional 17,743 shares during the period. Rhumbline Advisers’ holdings in Xencor were worth $3,907,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of XNCR. Louisiana State Employees Retirement System raised its holdings in Xencor by 13.0% during the fourth quarter. Louisiana State Employees Retirement System now owns 33,800 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 3,900 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Xencor by 12.7% during the fourth quarter. State of Alaska Department of Revenue now owns 39,773 shares of the biopharmaceutical company’s stock worth $913,000 after buying an additional 4,487 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Xencor by 10.2% during the fourth quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 1,944 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Xencor by 24.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 2,946 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 813 shares in the last quarter.

Xencor Stock Up 2.5 %

Shares of Xencor stock opened at $15.36 on Friday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $19.61 and its two-hundred day simple moving average is $20.64. The company has a market cap of $1.07 billion, a P/E ratio of -4.80 and a beta of 0.70. Xencor, Inc. has a 12-month low of $14.18 and a 12-month high of $27.24.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Buying and Selling

In other Xencor news, Director Alan Bruce Montgomery sold 13,301 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $27.03, for a total transaction of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 59.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.23% of the stock is currently owned by company insiders.

Analyst Ratings Changes

XNCR has been the subject of several recent analyst reports. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company reduced their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.